AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Study sponsor: Artiva Biotherapeutics, Inc. · ARTV
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-01Estimated
Enrollment · participants90Estimated
Source updated2026-07-31Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.